Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
University of Wisconsin, Madison
Duke University
Aeterna Zentaris GmbH
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00776867
First received: October 20, 2008
Last updated: August 27, 2014
Last verified: August 2014

October 20, 2008
August 27, 2014
October 2008
October 2015   (final data collection date for primary outcome measure)
Maximum Tolerated Dose (MTD) of perifosine monotherapy in children with cancer [ Time Frame: conclusion of the study ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00776867 on ClinicalTrials.gov Archive Site
  • To determine whether pharmacokinetic serum levels correlate with toxicity [ Time Frame: conclusion of the study ] [ Designated as safety issue: Yes ]
  • If previously resected tissue is available, determine whether molecular features predict response including Elevated PI3K/AKT/mTOR signaling, Elevated RAS/MAPK signaling, Cell cycle markers [ Time Frame: conclusion of the study ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

The purpose of this study is to test whether perifosine- a drug that inhibits the protein AKT, and has had some success in the treatment of adult cancers- is safe and effective in treating cancer. The investigators want to find out what effects, good and/or bad, it has on the patient and the cancer. The investigators are testing different dose schedules of perifosine and the patient will be asked to partake in one of the dose schedules.

Not Provided
Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Solid Tumors
Drug: perifosine
Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
Experimental: perifosine
This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level.
Intervention: Drug: perifosine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
36
October 2015
October 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Any solid tumor that failed standard therapy.
  • Patient must have evidence for tumor by CT, MRI, PET scan, MIBG scan, serum markers, or tissue sampling.
  • Age ≤ 21 years.
  • Karnofsky/Lansky performance status ≥ 50% (Karnofsky score for age> 16 years and Lansky score for age ≤ 16 years)
  • ANC≥ 1000 at least 24 hours off GCSF
  • Platelets ≥ 75k at least one week off platelet transfusions
  • Hg≥ 8g/dL at least one week off PRBC transfusion
  • AST ≤ 3 x the upper limit of normal
  • ALT ≤ 3 x the upper limit of normal
  • Total bilirubin ≤ 2.0 mg/dl
  • serum creatinine ≤ 1.5 x the upper limit of normal for age, or calculated creatinine clearance or nuclear GFR ≥ 70 ml/min/1.73 m2.
  • ≥ 3 weeks since last non-nitrosourea chemotherapy
  • ≥ 6 weeks since last nitrosoureas
  • ≥ 4 weeks since last RT
  • Patients must agree to practice adequate contraception. Females of childbearing potential must have a negative B-HCG pregnancy test documented within 14 days prior to drug initiation. Females must not be breast feeding.
  • Patients must be able to swallow tablets whole

Exclusion Criteria:

  • Pregnancy
  • Patients must not have active infection or serious intercurrent medical illness.
  • HIV-Positive patients receiving combination anti-retroviral therapy are excluded from the study due to possible retro-viral drug interactions. HIV testing not required.
  • Patients must not be taking EIAEDs. If patients were previously EIAEDs that have been discontinued, patients must have been off the agent for at least 2 weeks prior to registration.
Both
up to 21 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00776867
08-091
Not Provided
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
  • University of Wisconsin, Madison
  • Duke University
  • Aeterna Zentaris GmbH
Principal Investigator: Ira Dunkel, MD Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP